Emcure launches Poviztra: Affordable Wegovy alternative for India
Emcure Pharmaceuticals just dropped Poviztra, a second brand of the popular weight-loss drug Wegovy, thanks to a fresh partnership with Novo Nordisk.
With exclusive rights across India, Emcure is bringing this treatment to adults struggling with obesity or overweight issues—especially those dealing with conditions like high blood pressure or type 2 diabetes.
What makes Poviztra different?
Poviztra is priced at ₹8,790 per month for four doses—way less than the original Wegovy, which costs up to ₹26,050.
The goal? Make effective weight management more accessible in a country where millions face obesity-related health challenges.
How does it work?
The science behind Poviztra is all about semaglutide—a compound that mimics gut hormones to control blood sugar and curb appetite.
In clinical trials, one in three people lost over 20% of their body weight using this treatment compared to a placebo.
It's available in five strengths and comes as an easy-to-use weekly pen injector.